Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.

Mushrooms, psychedelics

Use of classic psychedelics may lower a person’s odds of developing opioid use disorder, said a new study published in the journal Scientific Reports.

Pear Therapeutics, Inc. has announced a program to offer patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool”, along with in-person care options.

Neurocrine Biosciences announced positive results from the company’s Phase III KINECT-HD study evaluating the efficacy of valbenazine in the treatment of chorea associated with Huntington’s Disease (HD).

Private drug discovery company Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.

More than half of the first 21 brains donated to the Australian Sports Brain Bank by former athletes showed signs of chronic traumatic encephalopathy (CTE), a degenerative disease caused by repeated concussions, a study showed.

Researchers have unlocked a key mechanism behind the genetic variant which could prove hopeful for new treatments for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The pandemic has undoubtedly altered the way of life for all Americans, but it has also shed light into the bleak statistics that are showing the opioid crisis is even worse than ever before. For the first time in history, the Centers for Disease Control and Prevention (CDC) reported that nearly 100,000 Americans died from drug overdoses over a 12-month period ending in March 2021, which was a little more than a 30 percent increase from the previous year.

Eisai Co. on Sept. 27 began the application process for the Japanese drugmaker’s experimental drug lecanemab for early Alzheimer’s disease using an accelerated approval pathway, the same path that helped Eisai’s development partner Biogen Inc. win U.S. approval of its medication in June.

The U.S. Food and Drug Administration granted breakthrough therapy designation to Japanese company Eisai and partner Biogen’s experimental therapy lecanemab for patients with early Alzheimer’s.